Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aytu Biopharma, Inc

NASDAQ: AYTU · Life Sciences · 4 alerts · CIK 1385818

Share price
$1.82Close, Nov 16
Market cap
$19.8M
Shares outstanding
10.87MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aytu Biopharma, Inc filings on SEC EDGAR ↗

4:28 PM ET 8-K
M&A Deal

Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.

Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.

“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”

Josh Disbrow, Chief Executive Officer of Aytu

“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

Josh Disbrow, Chief Executive Officer of Aytu
4:09 PM ET 8-K
M&A Deal

Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.

Counterparty
Rosemont Pharmaceuticals Holdings, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.